{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T01:34:33Z","timestamp":1793410473392,"version":"4.5.0"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:00:00Z","timestamp":1769126400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001449","name":"Alzheimer's Disease Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001449","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021856","name":"Ministero dell'Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100021856","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013278","name":"EU Joint Programme \u2013 Neurodegenerative Disease Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013278","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Regional Health - Europe"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.lanepe.2026.101609","type":"journal-article","created":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T16:17:05Z","timestamp":1770913025000},"page":"101609","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Anti-amyloid therapies and the transformation of Alzheimer's care pathways: early lessons from the frontline"],"prefix":"10.1016","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5485-0479","authenticated-orcid":false,"given":"Massimo","family":"Filippi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giordano","family":"Cecchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edoardo G.","family":"Spinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alma","family":"Ghirelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Rugarli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-0523-9965","authenticated-orcid":false,"given":"Stefano","family":"Pisano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Canu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Agosta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lanepe.2026.101609_bib1","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in early symptomatic alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial","volume":"330","author":"Sims","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.lanepe.2026.101609_bib2","first-page":"1631","article-title":"Lecanemab in early Alzheimer's disease","volume":"388","author":"van Dyck","year":"2023","journal-title":"Reply. N Engl J Med"},{"key":"10.1016\/j.lanepe.2026.101609_bib5","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s13195-025-01763-1","article-title":"Lecanemab in clinical practice: real-world outcomes in early Alzheimer's disease","volume":"17","author":"Bregman","year":"2025","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/j.lanepe.2026.101609_bib6","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1001\/jamaneurol.2025.1232","article-title":"Lecanemab treatment in a specialty memory clinic","volume":"82","author":"Paczynski","year":"2025","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.lanepe.2026.101609_bib7","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.14283\/jpad.2024.159","article-title":"Initial experience with lecanemab and lessons learned in 71 patients in a regional medical center","volume":"11","author":"Shields","year":"2024","journal-title":"J Prev Alzheimers Dis"},{"key":"10.1016\/j.lanepe.2026.101609_bib8","doi-asserted-by":"crossref","first-page":"362","DOI":"10.14283\/jpad.2023.30","article-title":"Lecanemab: appropriate use recommendations","volume":"10","author":"Cummings","year":"2023","journal-title":"J Prev Alzheimers Dis"},{"key":"10.1016\/j.lanepe.2026.101609_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.tjpad.2025.100150","article-title":"Donanemab: appropriate use recommendations","volume":"12","author":"Rabinovici","year":"2025","journal-title":"J Prev Alzheimers Dis"},{"key":"10.1016\/j.lanepe.2026.101609_bib10","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1212\/WNL.43.11.2412-a","article-title":"The clinical dementia rating (CDR): current version and scoring rules","volume":"43","author":"Morris","year":"1993","journal-title":"Neurology"},{"key":"10.1016\/j.lanepe.2026.101609_bib11","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1111\/j.1468-1331.1996.tb00423.x","article-title":"Mini-mental state examination: a normative study in Italian elderly population","volume":"3","author":"Magni","year":"1996","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.lanepe.2026.101609_bib12","series-title":"Alzheimer's Disease Assessment Scale.\u00b7Versione Italiana","author":"Fioravanti","year":"1996"},{"issue":"Suppl 2","key":"10.1016\/j.lanepe.2026.101609_bib13","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1097\/00002093-199700112-00005","article-title":"An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's disease cooperative study","volume":"11","author":"Galasko","year":"1997","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"10.1016\/j.lanepe.2026.101609_bib14","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/S1474-4422(23)00447-7","article-title":"European intersocietal recommendations for the biomarker-based diagnosis of neurocognitive disorders","volume":"23","author":"Frisoni","year":"2024","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.lanepe.2026.101609_bib15","doi-asserted-by":"crossref","first-page":"5143","DOI":"10.1002\/alz.13859","article-title":"Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's association workgroup","volume":"20","author":"Jack","year":"2024","journal-title":"Alzheimer's Dement"},{"key":"10.1016\/j.lanepe.2026.101609_bib16","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1001\/jama.2017.6669","article-title":"Association between elevated brain amyloid and subsequent cognitive decline among cognitively normal persons","volume":"317","author":"Donohue","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.lanepe.2026.101609_bib17","doi-asserted-by":"crossref","first-page":"802","DOI":"10.14283\/jpad.2024.122","article-title":"Amyloid and tau prediction of cognitive and functional decline in unimpaired older individuals: longitudinal data from the A4 and LEARN studies","volume":"11","author":"Sperling","year":"2024","journal-title":"J Prev Alzheimers Dis"},{"key":"10.1016\/j.lanepe.2026.101609_bib18","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3174\/ajnr.A8469","article-title":"Alzheimer disease anti-amyloid immunotherapies: imaging recommendations and practice considerations for monitoring of amyloid-related imaging abnormalities","volume":"46","author":"Cogswell","year":"2025","journal-title":"AJNR Am J Neuroradiol"},{"key":"10.1016\/j.lanepe.2026.101609_bib20","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1001\/jamaneurol.2025.0065","article-title":"Amyloid-related imaging abnormalities with donanemab in early symptomatic alzheimer disease: secondary analysis of the TRAILBLAZER-ALZ and ALZ 2 randomized clinical trials","volume":"82","author":"Zimmer","year":"2025","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.lanepe.2026.101609_bib21","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1001\/jamaneurol.2021.5205","article-title":"Amyloid-related imaging abnormalities and beta-amyloid-targeting antibodies: a systematic review","volume":"79","author":"Filippi","year":"2022","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.lanepe.2026.101609_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.tjpad.2025.100266","article-title":"The effect of modified donanemab titration on amyloid-related imaging abnormalities with edema\/effusions and amyloid reduction: 18-month results from TRAILBLAZER-ALZ 6","volume":"12","author":"Wang","year":"2025","journal-title":"J Prev Alzheimers Dis"},{"key":"10.1016\/j.lanepe.2026.101609_bib23","article-title":"Modified titration of donanemab reduces ARIA risk and maintains amyloid reduction","volume":"21","author":"Wang","year":"2025","journal-title":"Alzheimer's Dement"},{"key":"10.1016\/j.lanepe.2026.101609_bib24","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1177\/13872877251366657","article-title":"Reducing ARIA risk in Alzheimer's disease: Real-world impact of APOE genotype-guided slow titration with aducanumab and lecanemab","volume":"107","author":"Mervosh","year":"2025","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.lanepe.2026.101609_bib25","doi-asserted-by":"crossref","DOI":"10.1002\/alz.70491","article-title":"Donanemab exposure-response in early symptomatic Alzheimer's disease","volume":"21","author":"Gueorguieva","year":"2025","journal-title":"Alzheimer's Dement"},{"key":"10.1016\/j.lanepe.2026.101609_bib26","doi-asserted-by":"crossref","DOI":"10.1002\/alz.70997","article-title":"Treatment-related amyloid clearance (TRAC): a framework to characterize patients in the era of anti-amyloid therapies","volume":"21","author":"La Joie","year":"2025","journal-title":"Alzheimer's Dement"},{"key":"10.1016\/j.lanepe.2026.101609_bib27","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1177\/13872877251361051","article-title":"Safety of switching from lecanemab to donanemab in 20 consecutive patients with Alzheimer's disease","volume":"107","author":"Arai","year":"2025","journal-title":"J Alzheimers Dis"},{"issue":"4","key":"10.1016\/j.lanepe.2026.101609_bib28","doi-asserted-by":"crossref","first-page":"100096","DOI":"10.1016\/j.tjpad.2025.100096","article-title":"Real-world datasets for the International Registry for Alzheimer\u2019s Disease and Other Dementias (InRAD) and other registries: An international consensus","volume":"12","author":"Perneczky","year":"2025","journal-title":"J Prev Alzheimers Dis"}],"container-title":["The Lancet Regional Health - Europe"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666776226000219?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666776226000219?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T08:35:02Z","timestamp":1777883702000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666776226000219"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":25,"alternative-id":["S2666776226000219"],"URL":"https:\/\/doi.org\/10.1016\/j.lanepe.2026.101609","relation":{},"ISSN":["2666-7762"],"issn-type":[{"value":"2666-7762","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti-amyloid therapies and the transformation of Alzheimer's care pathways: early lessons from the frontline","name":"articletitle","label":"Article Title"},{"value":"The Lancet Regional Health - Europe","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lanepe.2026.101609","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.lanepe.2026.101631","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101609"}}